Germany’s ITM Medical Isotopes and Canada-based Isogen have signed a formal supply arrangement to provide a reliable supply of lutetium-177 to the world’s health care system using Canada’s Bruce Power reactors as a key supply source.
ITM Medical Isotopes is a subsidiary of the biotechnology and radiopharmaceutical group of companies - Isotopen Technologien München (ITM), and Isogen is a joint venture between France’s Framatome and Canada-based Kinectrics. The arrangement was made possible through Isogen’s partnership with Bruce Power, Canada’s only private sector nuclear energy generator, in combination with ITM’s know-how in the development of medical isotopes. It aims to ensure reliable, consistent supply of medical isotopes for use in targeted therapies for the next 15 years.
The agreement, based on a memorandum of understanding (MOU) signed in November 2019, defines the use of the new Isotope Production System (IPS) to be deployed in conjunction with ongoing Life-Extension work at the Bruce Power site. The IPS, designed and manufactured in Ontario by Isogen, offers functional flexibility, and will support the future production of other isotopes in addition to Lutetium-177.
To read more please visit:
Source: Nuclear Engineering International